Adhera Therapeutics Inc. and its wholly-owned subsidiaries, MDRNA Research Inc. (“MDRNA”), Cequent Pharmaceuticals Inc. (“Cequent”), Atossa Healthcare Inc. (“Atossa”), and IThenaPharma Inc. (“IThena”) (collectively “Adhera,” the “Company,” “we,” “our,” or “us”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evolving focus in anticipation of a return to a drug discovery and development company, and a departure from active commercialization and promotion of hypertension treatment options in the U.S. market. Previously throughout most of 2019, Adhera Therapeutics was a commercially focused entity that leveraged innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases with a focus on fixed dose combination therapies in hypertension. These efforts were primarily focused on Prestalia® , a single-pill FDC of perindopril arginine and amlodipine besylate, which we began marketing in June of 2018. Prestalia was developed in coordination with Les Laboratories, Servier, a French pharmaceutical conglomerate, that sells the formulation outside the United States under the brand names Coveram® . Prestalia was approved by the U.S. Food and Drug Administration (“FDA”) in January 2015, and was distributed through our patented DyrctAxess platform.
Company profile
Ticker
ATRX
Exchange
Website
CEO
Nancy R. Phelan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Marina Biotech, Inc., MDRNA, Inc., NASTECH PHARMACEUTICAL CO INC
SEC CIK
Corporate docs
Subsidiaries
IthenaPharma Inc. • Cequent Pharmaceuticals, Inc. • MDRNA Research, Inc. • Atossa HealthCare, Inc. ...
IRS number
112658569
ATRX stock data
Latest filings (excl ownership)
SEC STAFF ACTION
SEC staff action: Order
30 Jan 24
8-K
Termination of a Material Definitive Agreement
18 Jan 24
8-K
Departure of Directors or Certain Officers
16 Jan 24
8-K
Entry into a Material Definitive Agreement
29 Nov 23
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
8-K
Regulation FD Disclosure
12 Oct 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
8-K
Entry into a Material Definitive Agreement
29 Jun 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|